Japanese Journal of Clinical Oncology 31:573-583 (2001)
© 2001 Foundation for Promotion of Cancer Research
Review of a Personal Experience in the Management of Carcinomatosis and Sarcomatosis
Washington Cancer Institute, Washington, DC, USA
Background: Peritoneal surface malignancy can result from seeding of gastrointestinal cancer or abdomino-pelvic sarcoma; it can also occur as a primary disease, such as peritoneal mesothelioma. In the past, this clinical situation was treated only with palliative intent.
Methods: An aggressive approach to peritoneal surface malignancy involves peritonectomy procedures, perioperative intraperitoneal chemotherapy and knowledgeable patient selection. The clinical assessments necessary for valid clinical judgements include the cancer histopathology (invasive vs expansive progression), the preoperative abdominal and pelvic CT, the peritoneal cancer index and the completeness of cytoreduction score. Proper patient selection is mandatory for optimizing the results of treatment.
Results: In a series of phase II studies, appendiceal tumors with peritoneal seeding became the paradigm for success with an 85% long-term survival in selected patients. Carcinomatosis from colon cancer had an overall 5-year survival of 50% with selected patients. Also, sarcomatosis patients overall had a 40% 5-year survival in selected patients. Peritoneal mesothelioma showed a 36% 5-year survival. In all malignancies, early aggressive treatment of minimal peritoneal surface dissemination showed the greatest benefit.
Conclusions: Oncologists must accept responsibility for knowledgeable management of peritoneal surface dissemination of cancer because a curative approach has been demonstrated in large phase II studies and all historical controls show 0% long-term survival. Adjuvant phase III studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated.
+ For reprints and all correspondence: Paul H. Sugarbaker, Washington Cancer Institute, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA. E-mail: paul.sugarbaker@medstar.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. T. Johnson, K. M. Horton, and E. K. Fishman Nonvascular Mesenteric Disease: Utility of Multidetector CT with 3D Volume Rendering1 RadioGraphics, May 1, 2009; 29(3): 721 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mamede, T. Saga, H. Kobayashi, T. Ishimori, T. Higashi, N. Sato, M. W. Brechbiel, and J. Konishi Radiolabeling of Avidin with Very High Specific Activity for Internal Radiation Therapy of Intraperitoneally Disseminated Tumors Clin. Cancer Res., September 1, 2003; 9(10): 3756 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sano Is Peritoneal Carcinomatosis an Incurable Disease or Controllable Locoregional Condition? -- Challenge of Surgeons with Intraperitoneal Hyperthermic Chemotherapy Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 571 - 572. [Full Text] [PDF]
|
|